Centre for Medical Research & School of Psychiatry and Clinical Neurosciences, WA Centre for Health & Ageing, University of Western Australia, Perth, WA, Australia.
Neurology. 2010 Oct 26;75(17):1540-7. doi: 10.1212/WNL.0b013e3181f962c4. Epub 2010 Sep 22.
To investigate whether supplementing older men with vitamins B(12), B(6), and folic acid improves cognitive function.
The investigators recruited 299 community-representative hypertensive men 75 years and older to a randomized, double-blind controlled clinical trial of folic acid, vitamin B(6), and B(12) supplementation vs placebo over 2 years. The primary outcome of interest was the change in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog). A secondary aim of the study was to determine if supplementation with vitamins decreased the risk of cognitive impairment and dementia over 8 years.
The groups were well-balanced for demographic and biochemical parameters. There was no difference in the ADAS-cog change from baseline to 24 months between the placebo (0.8, SD 4.0) and vitamins group (0.7, SD 3.4). The adjusted scores in the treatment groups did not differ over time (placebo 0.2 lower, z = 0.71, p = 0.478). There was a nonsignificant 28% decrease in the risk of cognitive impairment (odds ratio 0.72, 95% confidence interval 0.25-2.09) and dementia (hazard ratio 0.72, 95% confidence interval 0.29-1.78) over 8 years of follow-up.
The daily supplementation of vitamins B(12), B(6), and folic acid does not benefit cognitive function in older men, nor does it reduce the risk of cognitive impairment or dementia.
This study provides Class I evidence that vitamin supplementation with daily doses of 500 μg [DOSAGE ERROR CORRECTED] of B(12), 2 mg of folic acid, and 25 mg of B(6) over 2 years does not improve cognitive function in hypertensive men aged 75 and older.
研究补充维生素 B(12)、B(6)和叶酸是否能改善老年男性的认知功能。
研究人员招募了 299 名社区代表性的 75 岁及以上高血压男性,进行了一项为期 2 年的叶酸、维生素 B(6)和 B(12)补充剂与安慰剂的随机、双盲对照临床试验。主要研究结果是阿尔茨海默病评估量表(ADAS-cog)认知子量表的变化。该研究的次要目的是确定补充维生素是否能降低 8 年内认知障碍和痴呆的风险。
两组在人口统计学和生化参数方面平衡良好。安慰剂组(0.8,SD 4.0)和维生素组(0.7,SD 3.4)从基线到 24 个月的 ADAS-cog 变化无差异。治疗组的调整后评分随时间无差异(安慰剂组低 0.2,z = 0.71,p = 0.478)。在 8 年的随访中,认知障碍的风险无显著降低(比值比 0.72,95%置信区间 0.25-2.09),痴呆的风险也无显著降低(风险比 0.72,95%置信区间 0.29-1.78)。
每日补充维生素 B(12)、B(6)和叶酸对老年男性的认知功能没有益处,也不能降低认知障碍或痴呆的风险。
本研究提供了 I 级证据,表明每日补充 500μg[剂量错误修正]B(12)、2mg 叶酸和 25mg B(6)持续 2 年不能改善 75 岁及以上高血压男性的认知功能。